StockNews.com Upgrades iBio (NYSE:IBIO) to Sell

iBio (NYSE:IBIO) was upgraded by equities researchers at StockNews.com to a “sell” rating in a note issued to investors on Tuesday.

iBio Price Performance

Shares of NYSE IBIO opened at $4.39 on Tuesday. The business has a fifty day moving average price of $3.89 and a 200 day moving average price of $2.93. The company has a debt-to-equity ratio of 0.05, a quick ratio of 1.76 and a current ratio of 1.76. iBio has a 1-year low of $1.05 and a 1-year high of $6.89.

Insider Activity

In other news, Director David Arkowitz purchased 18,382 shares of the stock in a transaction dated Friday, January 10th. The shares were purchased at an average cost of $2.72 per share, with a total value of $49,999.04. Following the completion of the purchase, the director now directly owns 18,382 shares of the company’s stock, valued at approximately $49,999.04. The trade was a ∞ increase in their position. The transaction was disclosed in a document filed with the SEC, which is available through this link. Company insiders own 0.58% of the company’s stock.

Hedge Funds Weigh In On iBio

An institutional investor recently raised its position in iBio stock. Geode Capital Management LLC raised its stake in iBio, Inc. (NYSE:IBIO) by 52.3% during the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 83,797 shares of the company’s stock after purchasing an additional 28,775 shares during the period. Geode Capital Management LLC owned about 0.85% of iBio worth $205,000 as of its most recent filing with the Securities and Exchange Commission (SEC). 7.90% of the stock is owned by institutional investors.

About iBio

iBio, Inc, a biotechnology company, engages in the development of precision antibodies in the United States. It offers IBIO-100, a preclinical anti-fibrotic program for the treatment of systemic scleroderma and idiopathic pulmonary fibrosis; and EngageTx platform, which provides an optimized CD3 T-cell engager antibody panel.